Augmenix tissue-marking product for surgeries gets FDA clearance

By Chris Reidy, Globe Staff

Augmenix Inc., a Waltham company focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology, said Monday that it has received clearance from the US Food and Drug Administration to market an absorbable tissue marker visible that helps medical personnel to plan surgical procedures.

The product is called TraceIT Tissue Marker, and it is designed to “radiographically mark soft tissue during a surgical procedure or for future surgical procedures,” Augmenix said in a press release.

Augmenix describes TraceIT Tissue Marker as a synthetic hydrogel consisting primarily of water and iodinated cross-linked polyethylene glycol.Small hydrogel injections are clearly visible in the lung, breast, prostate, and other tissues, the release said.